Lung events hit tivantinib's Asian NSCLC trial but Western Ph III study still on track
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin has stopped patient enrolment in the Phase III ATTENTION clinical trial in Asia for the ArQule cancer drug tivantinib due to cases of interstitial lung disease (ILD), but ArQule says the move will not impact its ongoing 1,000-patient Phase III MARQUEE trial being conducted with Daiichi Sankyo in the Americas, Europe and other regions.